Skip to main content
Top
Published in: Abdominal Radiology 5/2017

01-05-2017

Evaluation of infectious complications following percutaneous liver ablation in patients with bilioenteric anastomoses

Authors: B. T. Welch, J. J. Schmitz, T. D. Atwell, A. M. McGauvran, A. N. Kurup, M. R. Callstrom, G. D. Schmit

Published in: Abdominal Radiology | Issue 5/2017

Login to get access

Abstract

Purpose

Prior bilioenteric anastomosis (BEA) has been associated with elevated risk of abscess formation after thermal ablation of hepatic tumors. We assessed the incidence of hepatic abscess after thermal ablation in a BEA cohort treated with extended antibiotic regimens following ablation.

Materials and methods

Retrospective review was performed to identify patients with BEA who underwent percutaneous hepatic thermal ablation between January 1, 2003–September 1, 2016. Fifteen patients with BEA underwent 18 percutaneous thermal ablation procedures. Patient and procedural characteristics were reviewed, as well as the antibiotic regiment utilized post ablation. Complications were characterized via standardized nomenclature [Common Terminology for Clinically Adverse Events (CTCAE) v4.03].

Results

Fifteen patients with BEA underwent treatment of 49 liver lesions during 18 ablation sessions. Mean follow-up in these patients was 39 months (range 3–138 months). Two patients (11%) developed hepatic abscesses, both of which occurred within 45 days of the ablation procedure while the patients were still on extended prophylactic antibiotic therapy. No additional CTCAE clinically significant complications were observed.

Conclusion

Thermal ablation of hepatic tumors can be accomplished safely in patients with BEA. Long-term post-procedural antibiotics may mitigate the risk of hepatic abscess formation. Due to the high number of patients who are deemed surgically unresectable, patients with BEA may have limited alternate treatment modalities and percutaneous hepatic thermal ablative treatments warrant consideration.
Literature
1.
go back to reference Clark ME, Smith RR (2014) Liver-directed therapies in metastatic colorectal cancer. J gastrointest oncol 5(5):374–387PubMedPubMedCentral Clark ME, Smith RR (2014) Liver-directed therapies in metastatic colorectal cancer. J gastrointest oncol 5(5):374–387PubMedPubMedCentral
2.
go back to reference Foltz G (2014) Image-guided percutaneous ablation of hepatic malignancies. Semin Interv Radiol 31(2):180–186CrossRef Foltz G (2014) Image-guided percutaneous ablation of hepatic malignancies. Semin Interv Radiol 31(2):180–186CrossRef
3.
go back to reference Murata S, Mine T, Sugihara F, et al. (2014) Interventional treatment for unresectable hepatocellular carcinoma. World J Gastroenterol 20(37):13453–13465CrossRef Murata S, Mine T, Sugihara F, et al. (2014) Interventional treatment for unresectable hepatocellular carcinoma. World J Gastroenterol 20(37):13453–13465CrossRef
4.
go back to reference Saied A, Katz SC, Espat NJ (2013) Regional hepatic therapies: an important component in the management of colorectal cancer liver metastases. Hepatobiliary Surg Nutr 2(2):97–107PubMedPubMedCentral Saied A, Katz SC, Espat NJ (2013) Regional hepatic therapies: an important component in the management of colorectal cancer liver metastases. Hepatobiliary Surg Nutr 2(2):97–107PubMedPubMedCentral
5.
go back to reference Solbiati L, Ahmed M, Cova L, et al. (2012) Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology 265(3):958–968CrossRef Solbiati L, Ahmed M, Cova L, et al. (2012) Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology 265(3):958–968CrossRef
6.
go back to reference Akahane M, Koga H, Kato N, et al. (2005) Complications of percutaneous radiofrequency ablation for hepato-cellular carcinoma: imaging spectrum and management. Radiographics 25(Suppl 1):S57–68CrossRef Akahane M, Koga H, Kato N, et al. (2005) Complications of percutaneous radiofrequency ablation for hepato-cellular carcinoma: imaging spectrum and management. Radiographics 25(Suppl 1):S57–68CrossRef
7.
go back to reference de Baere T, Risse O, Kuoch V, et al. (2003) Adverse events during radiofrequency treatment of 582 hepatic tumors. Am J Roentgenol 181(3):695–700CrossRef de Baere T, Risse O, Kuoch V, et al. (2003) Adverse events during radiofrequency treatment of 582 hepatic tumors. Am J Roentgenol 181(3):695–700CrossRef
8.
go back to reference Hoffmann R, Rempp H, Schmidt D, et al. (2012) Prolonged antibiotic prophylaxis in patients with bilioenteric anastomosis undergoing percutaneous radiofrequency ablation. J Vasc Interv Radiol 23(4):545–551CrossRef Hoffmann R, Rempp H, Schmidt D, et al. (2012) Prolonged antibiotic prophylaxis in patients with bilioenteric anastomosis undergoing percutaneous radiofrequency ablation. J Vasc Interv Radiol 23(4):545–551CrossRef
9.
go back to reference Fonseca AZ, Santin S, Gomes LG, et al. (2014) Complications of radiofrequency ablation of hepatic tumors: frequency and risk factors. World J Hepatol 6(3):107–113CrossRef Fonseca AZ, Santin S, Gomes LG, et al. (2014) Complications of radiofrequency ablation of hepatic tumors: frequency and risk factors. World J Hepatol 6(3):107–113CrossRef
10.
go back to reference Choi D, Lim HK, Kim MJ, et al. (2005) Liver abscess after percutaneous radiofrequency ablation for hepatocellular carcinomas: frequency and risk factors. Am J Roentgenol 184(6):1860–1867CrossRef Choi D, Lim HK, Kim MJ, et al. (2005) Liver abscess after percutaneous radiofrequency ablation for hepatocellular carcinomas: frequency and risk factors. Am J Roentgenol 184(6):1860–1867CrossRef
11.
go back to reference Elias D, Di Pietroantonio D, Gachot B, et al. (2006) Liver abscess after radiofrequency ablation of tumors in patients with a biliary tract procedure. Gastroenterol Clin Biol 30(6–7):823–827CrossRef Elias D, Di Pietroantonio D, Gachot B, et al. (2006) Liver abscess after radiofrequency ablation of tumors in patients with a biliary tract procedure. Gastroenterol Clin Biol 30(6–7):823–827CrossRef
12.
go back to reference Livraghi T, olbiati L, Meloni MF, et al. (2003) Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 226(2):441–451CrossRef Livraghi T, olbiati L, Meloni MF, et al. (2003) Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 226(2):441–451CrossRef
13.
go back to reference Shibata T, Yamamoto Y, Yamamoto N, et al. (2003) Cholangitis and liver abscess after percutaneous ablation therapy for liver tumors: incidence and risk factors. J Vasc Interv Radiol 14(12):1535–1542CrossRef Shibata T, Yamamoto Y, Yamamoto N, et al. (2003) Cholangitis and liver abscess after percutaneous ablation therapy for liver tumors: incidence and risk factors. J Vasc Interv Radiol 14(12):1535–1542CrossRef
14.
go back to reference Iida H, Aihara T, Ikuta S, Yamanaka N (2014) Risk of abscess formation after liver tumor radiofrequency ablation: a review of 8 cases wtih a history of enterobiliary anastomosis. Hepato-gastroenterology 61(135):1867–1870PubMed Iida H, Aihara T, Ikuta S, Yamanaka N (2014) Risk of abscess formation after liver tumor radiofrequency ablation: a review of 8 cases wtih a history of enterobiliary anastomosis. Hepato-gastroenterology 61(135):1867–1870PubMed
15.
go back to reference Odisio BC, Richter M, Aloia TA, et al. (2016) Use of prophylactic antibiotics to prevent abscess formation following hepatic ablation in patients with prior enterobiliary manipulation. J Gastrointest Surg 20(8):1428–1434CrossRef Odisio BC, Richter M, Aloia TA, et al. (2016) Use of prophylactic antibiotics to prevent abscess formation following hepatic ablation in patients with prior enterobiliary manipulation. J Gastrointest Surg 20(8):1428–1434CrossRef
16.
go back to reference Welch BT, Callstrom MR, Carpenter PC, et al. (2014) A single-institution experience in image-guided thermal ablation of adrenal gland metastases. J Vasc Interv Radiol 25(4):593–598CrossRef Welch BT, Callstrom MR, Carpenter PC, et al. (2014) A single-institution experience in image-guided thermal ablation of adrenal gland metastases. J Vasc Interv Radiol 25(4):593–598CrossRef
17.
go back to reference Welch BT, Callstrom MR, Morris JM, et al. (2014) Feasibility and oncologic control following percutaneous image-guided ablation of metastatic renal cell carcinoma. J Urol 192:357–363CrossRef Welch BT, Callstrom MR, Morris JM, et al. (2014) Feasibility and oncologic control following percutaneous image-guided ablation of metastatic renal cell carcinoma. J Urol 192:357–363CrossRef
18.
go back to reference National Cancer Institute (2009) Common terminology criteria for adverse events (CTCAE) version 4.0. National Cancer Institute (2009) Common terminology criteria for adverse events (CTCAE) version 4.0.
Metadata
Title
Evaluation of infectious complications following percutaneous liver ablation in patients with bilioenteric anastomoses
Authors
B. T. Welch
J. J. Schmitz
T. D. Atwell
A. M. McGauvran
A. N. Kurup
M. R. Callstrom
G. D. Schmit
Publication date
01-05-2017
Publisher
Springer US
Published in
Abdominal Radiology / Issue 5/2017
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-017-1051-5

Other articles of this Issue 5/2017

Abdominal Radiology 5/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.